
DEADLINE APPROACHING: Berger Montague Advises ChampionX Corporation (CHX) Investors to Inquire About a Securities Fraud Class Action by July 14, 2026
Newsfile Corp
Published: Jul 03, 2026, 01:21 AM GMT+9
Sentiment Analysis
National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ChampionX Corporation (NASDAQ: CHX) ("ChampionX" or the "Company") on behalf of investors who sold ChampionX common stock during the period from February 29, 2024 through April 1, 2024 (the "Class Period"). Investor Deadline: Investors who sold ChampionX common stock during the Class Period may, no later than July 14, 2026 , seek to be appointed as a lead plaintiff representative of the class.
Prior to its July 2025 acquisition by SLB, ChampionX was a global leader in chemistry solutions and engineered equipment for the oil and gas industry. The lawsuit alleges that while ChampionX and its senior executives were in possession of material, non-public information - specifically, unsolicited acquisition offers from SLB - the Company repurchased a significant amount of its own shares at market prices artificially deflated by the concealment of that information.
Specifically, on February 29, 2024, ChampionX received an unsolicited, non-public offer from SLB to acquire all outstanding shares of ChampionX for $36.70 per share. On March 7, 2024, SLB raised its offer to $37.80 per share. Throughout the Class Period, ChampionX's average stock price was $33.32 per share - materially below the undisclosed offer prices.
Despite having an obligation to either disclose the acquisition offers or abstain from purchasing ChampionX stock, the Company continued to repurchase shares at those depressed prices and benefitted significantly from keeping this information from investors.
On April 2, 2024, during pre-market hours, ChampionX disclosed that it had reached an agreement to be acquired by SLB. The merger eventually closed on July 16, 2025, with SLB acquiring ChampionX for $40.58 per share.
Source: Newsfile Corp
This content is not intended as investment advice or a recommendation. Any opinions expressed are solely the personal views of each article.